Estudio coste-beneficio de la vacunación contra varicela en Aragón [A cost-benefit analysis of varicella vaccination in Aragon]
Peña Blasco, Guillermo (Universidad de Zaragoza) ; Blasco Pérez-Aramendía, María Jesús (Universidad de Zaragoza)![Estudio coste-beneficio de la vacunación contra varicela en Aragón [A cost-benefit analysis of varicella vaccination in Aragon]](https://zaguan.unizar.es/record/63227/files/texto_completo.jpg?subformat=icon)
Resumen: Fundamento: La varicela, enfermedad infecto- contagiosa que afecta a la infancia de forma benigna, puede complicarse en adultos y niños vulnerables y ser mortal. Existen vacunas eficaces. Se estudiaron retrospectivamente los costes que supuso esta enfermedad en la población aragonesa en el período 2004-2014 y las hospitalizaciones generadas. Se compararon con los gastos que supondría haber vacunado a esas personas y también los gastos de vacunar a la población de 1 año de edad durante todo ese período. Mediante un análisis coste-beneficio, se evaluó el impacto económico de la vacunación. Método: Se utilizaron datos de la Autonomía de Aragón (España) de estos 11 años (incidencia anual de varicela, altas hospitalarias por este motivo, precio de la consulta de atención primaria y de hospitalización de cada año, así como el coste de días de trabajo según el salario mínimo anual y medicaciones utilizadas). Se calcularon los costes capitalizados, se compararon con los gastos capitalizados de vacunación y se realizó un análisis de sensibilidad. Resultados: Se obtuvo un índice beneficio-coste de 1, 6 vacunando y revacunando a todos los niños que se enfermaron. Resultó un índice beneficio- coste de 1, 24 al vacunar a toda la población de 12 meses con vacuna de 28, 59€. En estos 11 años, el 53% de las hospitalizaciones fueron niños menores de 5 años. Conclusiones: Las campañas públicas de vacunación con 2 dosis a población menor de 4 años suponen ahorro y rentabilidad porque el precio de la vacuna permite un índice beneficio-coste superior a 1. Es esperable una gran disminución de hospitalizaciones en la población de 3-4 años.
Background. Varicella, a contagious and infectious disease that is usually benign in children, may become complicated among adults and vulnerable children and may even be life-threatening. There are effective vaccines. A retrospective study was conducted about costs and resulting hospitalizations related to this disease in the population of Aragon in the 2004-2014 period. Costs were compared to the expenses that would have been incurred if those people had received the vaccine and also to the expenses of vaccinating the 1-year-old population over the entire period. A cost-benefit analysis was done to assess the economic impact of varicella vaccination. Method. Data for the 11-year period were provided by the Autonomous Community of Aragon (Spain) and induded annual varicella incidence, hospital discharges of varicella cases, costs of primary health care visits and hospitalizations for each year, costs of each workday as per the minimum annual salary and of drugs used). Capitalized costs were estimated and compared to capitalized expenses of vaccination, and a sensitivity analysis was performed. Results. A benefit-cost ratio of 1.6 was obtained considering that all children who had varicella had been vaccinated and had received a booster dose. A benefit-cost ratio of 1.24 was obtained considering that the vaccine had been administered to every 1-year-old individual at a price of EUR 28.59 per vaccine. Over the 11-year period, 53% of hospitalizations corresponded to children younger than 5 years old. Conclusions. Public campaigns for the immunization of children younger than 4 years old with 2 doses lead to cost savings and are cost-effective because the vaccine price results in a benefit-cost ratio greater than 1. A major reduction is expected in the number of hospitalizations among children aged 3-4 years.
Idioma: Múltiples idiomas
DOI: 10.5546/aap.2017.432
Año: 2017
Publicado en: Archivos Argentinos de Pediatria 115, 5 (2017), 432-438
ISSN: 0325-0075
Factor impacto JCR: 0.405 (2017)
Categ. JCR: PEDIATRICS rank: 118 / 124 = 0.952 (2017) - Q4 - T3
Factor impacto SCIMAGO: 0.184 - Pediatrics, Perinatology and Child Health (Q3)
Tipo y forma: Article (Published version)
Área (Departamento): Área Economía Aplicada (Dpto. Estruc.Hª Econ.y Eco.Pb.)
Área (Departamento): Área Pediatría (Dpto. Pediatría Radiol.Med.Fís)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material.
Exportado de SIDERAL (2022-12-02-14:36:19)
Visitas y descargas
Background. Varicella, a contagious and infectious disease that is usually benign in children, may become complicated among adults and vulnerable children and may even be life-threatening. There are effective vaccines. A retrospective study was conducted about costs and resulting hospitalizations related to this disease in the population of Aragon in the 2004-2014 period. Costs were compared to the expenses that would have been incurred if those people had received the vaccine and also to the expenses of vaccinating the 1-year-old population over the entire period. A cost-benefit analysis was done to assess the economic impact of varicella vaccination. Method. Data for the 11-year period were provided by the Autonomous Community of Aragon (Spain) and induded annual varicella incidence, hospital discharges of varicella cases, costs of primary health care visits and hospitalizations for each year, costs of each workday as per the minimum annual salary and of drugs used). Capitalized costs were estimated and compared to capitalized expenses of vaccination, and a sensitivity analysis was performed. Results. A benefit-cost ratio of 1.6 was obtained considering that all children who had varicella had been vaccinated and had received a booster dose. A benefit-cost ratio of 1.24 was obtained considering that the vaccine had been administered to every 1-year-old individual at a price of EUR 28.59 per vaccine. Over the 11-year period, 53% of hospitalizations corresponded to children younger than 5 years old. Conclusions. Public campaigns for the immunization of children younger than 4 years old with 2 doses lead to cost savings and are cost-effective because the vaccine price results in a benefit-cost ratio greater than 1. A major reduction is expected in the number of hospitalizations among children aged 3-4 years.
Idioma: Múltiples idiomas
DOI: 10.5546/aap.2017.432
Año: 2017
Publicado en: Archivos Argentinos de Pediatria 115, 5 (2017), 432-438
ISSN: 0325-0075
Factor impacto JCR: 0.405 (2017)
Categ. JCR: PEDIATRICS rank: 118 / 124 = 0.952 (2017) - Q4 - T3
Factor impacto SCIMAGO: 0.184 - Pediatrics, Perinatology and Child Health (Q3)
Tipo y forma: Article (Published version)
Área (Departamento): Área Economía Aplicada (Dpto. Estruc.Hª Econ.y Eco.Pb.)
Área (Departamento): Área Pediatría (Dpto. Pediatría Radiol.Med.Fís)
You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use. You may not use the material for commercial purposes. If you remix, transform, or build upon the material, you may not distribute the modified material. Exportado de SIDERAL (2022-12-02-14:36:19)
Permalink:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Articles
Record created 2017-11-16, last modified 2022-12-02